Tissue engineering and regenerative medicine: Recent innovations and the transition to translation

Tissue Engineering - Part B: Reviews

Volumn 19, Issue 1, 2013, Pages 1-13

  Fisher, Matthew B ^a,c   Mauck, Robert L ^a,b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SOURCES; CLINICAL TRIAL; HIGH IMPACT; OBJECTIVE ANALYSIS; PLURIPOTENT STEM CELLS; REGENERATIVE MEDICINE; TERM FIELD; TISSUE FORMATION;

STEM CELLS; TISSUE;

SCAFFOLDS (BIOLOGY);

BIOMATERIAL; BONE MORPHOGENETIC PROTEIN 2; MICRORNA; TRANSFORMING GROWTH FACTOR BETA;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BLADDER BIOPSY; BONE REGENERATION; CELL DIFFERENTIATION; CELL TYPE; CORONARY STENT; GENE EXPRESSION; HEART INFARCTION; HUMAN; LYMPHOCYTIC INFILTRATION; MOLECULAR MECHANICS; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; T LYMPHOCYTE; THROMBOCYTE RICH PLASMA; TISSUE ENGINEERING;

ANIMALS; HUMANS; REGENERATIVE MEDICINE; TISSUE ENGINEERING; TISSUE SCAFFOLDS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84873356816     PISSN: 19373368     EISSN: 19373376     Source Type: Journal    
DOI: 10.1089/ten.teb.2012.0723     Document Type: Review

References (106)

1. Lysaght, M.J., and Crager, J. Origins. Tissue Eng Part A 15, 1449, 2009.
2. Lysaght, M.J., and Hazlehurst, A.L. Tissue engineering: the end of the beginning. Tissue Eng 10, 309, 2004.
3. Lysaght, M.J., Jaklenec, A., and Deweerd, E. Great expectations: private sector activity in tissue engineering, regenerative medicine, and stem cell therapeutics. Tissue Eng Part A 14, 305, 2008.
4. Lysaght, M.J., and Reyes, J. The growth of tissue engineering. Tissue Eng 7, 485, 2001.
5. Lysaght, M.J. Product development in tissue engineering. Tissue Eng 1, 221, 1995.
6. Langer, R., and Vacanti, J.P. Tissue engineering. Science 260, 920, 1993.
7. Zuk, P.A., et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 7, 211, 2001.
8. Hartgerink, J.D., Beniash, E., and Stupp, S.I. Self-assembly and mineralization of peptide-amphiphile nanofibers. Science 294, 1684, 2001.
9. Willert, K., et al. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 423, 448, 2003.
10. Nakagawa, M., et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 26, 101, 2008.
11. Sato, N., et al. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med 10, 55, 2004.
12. Li, W.J., et al. Electrospun nanofibrous structure: a novel scaffold for tissue engineering. J Biomed Mater Res 60, 613, 2002.
13. Niklason, L.E., et al. Functional arteries grown in vitro. Science 284, 489, 1999.
14. Altman, G.H., et al. Silk-based biomaterials. Biomaterials 24, 401, 2003.
15. Kehat, I., et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest 108, 407, 2001.
16. Matthews, J.A., et al. Electrospinning of collagen nanofi-bers. Biomacromolecules 3, 232, 2002.
17. Yamashita, J., et al. Flk1-positive cells derived from embryonic stem cells serve as vascular progenitors. Nature 408, 92, 2000.
18. Liechty, K.W., et al. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med 6, 1282, 2000.
19. Yoshimoto, H., et al. A biodegradable nanofiber scaffold by electrospinning and its potential for bone tissue engineering. Biomaterials 24, 2077, 2003.
20. Okita, K., et al. Generation of mouse induced pluripotent stem cells without viral vectors. Science 322, 949, 2008.
21. Meissner, A., et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 454, 766, 2008.
22. Kokubo, T., Kim, H.M., and Kawashita, M. Novel bioactive materials with different mechanical properties. Biomater-ials 24, 2161, 2003.
23. Madihally, S.V., and Matthew, H.W. Porous chitosan scaffolds for tissue engineering. Biomaterials 20, 1133, 1999.
24. Boyan, B.D., et al. Role of material surfaces in regulating bone and cartilage cell response. Biomaterials 17, 137, 1996.
25. Le Blanc, K., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371, 1579, 2008.
26. Macchiarini, P., et al. Clinical transplantation of a tissue-engineered airway. Lancet 372, 2023, 2008.
27. Badylak, S.F. The extracellular matrix as a biologic scaffold material. Biomaterials 28, 3587, 2007.
28. Badylak, S.F., Freytes, D.O., and Gilbert, T.W. Extracellular matrix as a biological scaffold material: structure and function. Acta Biomater 5, 1, 2009.
29. Petersen, T.H., et al. Tissue-engineered lungs for in vivo implantation. Science 329, 538, 2010.
30. Ott, H.C., et al. Regeneration and orthotopic transplantation of a bioartificial lung. Nat Med 16, 927, 2010.
31. Uygun, B.E., et al. Organ reengineering through development of a transplantable recellularized liver graft using decellularized liver matrix. Nat Med 16, 814, 2010.
32. Wilshaw, S.P., et al. Development and characterization of acellular allogeneic arterial matrices. Tissue Eng Part A 18, 471, 2012.
33. Dahl, S.L., et al. Readily available tissue-engineered vascular grafts. Sci Transl Med 3, 68ra9, 2011.
34. Daly, A.B., et al. Initial binding and recellularization of decellularized mouse lung scaffolds with bone marrow-derived mesenchymal stromal cells. Tissue Eng Part A 18, 1, 2012.
35. Sarig, U., et al. Thick acellular heart extracellular matrix with inherent vasculature: a potential platform for myo-cardial tissue regeneration. Tissue Eng Part A 18, 2125, 2012.
36. Coquelin, L., et al. In vivo and in vitro comparison of three different allografts vitalized with human mesenchymal stromal cells. Tissue Eng Part A 18, 1921, 2012.
37. Kang, S.B., et al. Functional recovery of completely dener-vated muscle: implications for innervation of tissue-engineered muscle. Tissue Eng Part A 18, 1912, 2012.
38. Baker, B.M., et al. Sacrificial nanofibrous composites provide instruction without impediment and enable functional tissue formation. Proc Natl Acad Sci USA 109, 14176, 2012.
39. Coburn, J.M., et al. Bioinspired nanofibers support chon-drogenesis for articular cartilage repair. Proc Natl Acad Sci USA 109, 10012, 2012.
40. McCullen, S.D., et al. Anisotropic fibrous scaffolds for articular cartilage regeneration. Tissue Eng Part A 18, 2073, 2012.
41. Fisher, M.B., et al. Organized nanofibrous scaffolds that mimic the macroscopic and microscopic architecture of the knee meniscus. Acta Biomater 9, 4496, 2012.
42. Sukegawa, A., et al. Repair of rabbit osteochondral defects by an acellular technique with an ultrapurified alginate gel containing stromal cell-derived factor-1. Tissue Eng Part A 18, 934, 2012.
43. Liu, X., Jin, X., and Ma, P.X. Nanofibrous hollow micro-spheres self-assembled from star-shaped polymers as in-jectable cell carriers for knee repair. Nat Mater 10, 398, 2011.
44. Miller, J.S., et al. Rapid casting of patterned vascular networks for perfusable engineered three-dimensional tissues. Nat Mater 11, 768, 2012.
45. Hanjaya-Putra, D., et al. Controlled activation of morphogenesis to generate a functional human microvasculature in a synthetic matrix. Blood 118, 804, 2011.
46. Ma, J., et al. Three-dimensional engineered bone-ligament-bone constructs for anterior cruciate ligament replacement. Tissue Eng Part A 18, 103, 2012.
47. Kolambkar, Y.M., et al. An alginate-based hybrid system for growth factor delivery in the functional repair of large bone defects. Biomaterials 32, 65, 2011.
48. Fisher, M.B., et al. Potential of healing a transected anterior cruciate ligament with genetically modified extracellular matrix bioscaffolds in a goat model. Knee Surg Sports Traumatol Arthrosc 20, 1357, 2012.
49. Jaskelioff, M., et al. Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. Nature 469, 102, 2011.
50. Porrello, E.R., et al. Transient regenerative potential of the neonatal mouse heart. Science 331, 1078, 2011.
51. Joe, A.W., et al. Muscle injury activates resident fibro/adi-pogenic progenitors that facilitate myogenesis. Nat Cell Biol 12, 153, 2010.
52. Smart, N., et al. De novo cardiomyocytes from within the activated adult heart after injury. Nature 474, 640, 2011.
53. Lee, S., et al. Distinct macrophage phenotypes contribute to kidney injury and repair. J Am Soc Nephrol 22, 317, 2011.
54. Sindrilaru, A., et al. An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. J Clin Invest 121, 985, 2011.
55. Brown, B.N., et al. Macrophage polarization: an opportunity for improved outcomes in biomaterials and regenerative medicine. Biomaterials 33, 3792, 2012.
56. Rinkevich, Y., et al. Germ-layer and lineage-restricted stem/progenitors regenerate the mouse digit tip. Nature 476, 409, 2011.
57. Seifert, A.W., et al. Skin shedding and tissue regeneration in African spiny mice (Acomys). Nature 489, 561, 2012.
58. Lee, C.H., et al. Regeneration of the articular surface of the rabbit synovial joint by cell homing: a proof of concept study. Lancet 376, 440, 2010.
59. Shah, R.N., et al. Supramolecular design of self-assembling nanofibers for cartilage regeneration. Proc Natl Acad Sci USA 107, 3293, 2010.
60. Zhao, X., et al. Active scaffolds for on-demand drug and cell delivery. Proc Natl Acad Sci USA 108, 67, 2011.
61. Doorn, J., et al. Therapeutic applications of mesenchymal stromal cells: paracrine effects and potential improvements. Tissue Eng Part B Rev 18, 101, 2012.
62. Lai, R.C., et al. Exosome secreted by MSC reduces myo-cardial ischemia/reperfusion injury. Stem Cell Res 4, 214, 2010.
63. Chimenti, I., et al. Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. Circ Res 106, 971, 2010.
64. Loffredo, F.S., et al. Bone marrow-derived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair. Cell Stem Cell 8, 389, 2011.
65. Tang, W., et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 332, 478, 2011.
66. Le Visage, C., et al. Mesenchymal stem cell delivery into rat infarcted myocardium using a porous polysaccharide-based scaffold: a quantitative comparison with endocardial injection. Tissue Eng Part A 18, 35, 2012.
67. Marklein, R.A. and Burdick, J.A. Controlling stem cell fate with material design. Adv Mater 22, 175, 2010.
68. Kloxin, A.M., Benton, J.A., and Anseth, K.S. In situ elasticity modulation with dynamic substrates to direct cell pheno-type. Biomaterials 31, 1, 2010.
69. Yin, Z., et al. The regulation of tendon stem cell differentiation by the alignment of nanofibers. Biomaterials 31, 2163, 2010.
70. Yuan, H., et al. Osteoinductive ceramics as a synthetic alternative to autologous bone grafting. Proc Natl Acad Sci USA 107, 13614, 2010.
71. Gonzalez-Cruz, R.D., Fonseca, V.C., and Darling, E.M. Cellular mechanical properties reflect the differentiation potential of adipose-derived mesenchymal stem cells. Proc Natl Acad Sci USA 109, E1523, 2012.
72. Hur, S.C., et al. Deformability-based cell classification and enrichment using inertial microfluidics. Lab Chip 11, 912, 2011.
73. Schriebl, K., et al. Selective removal of undifferentiated human embryonic stem cells using magnetic activated cell sorting followed by a cytotoxic antibody. Tissue Eng Part A 18, 899, 2012.
74. Raya-Rivera, A., et al. Tissue-engineered autologous urethras for patients who need reconstruction: an observational study. Lancet 377, 1175, 2011.
75. Makkar, R.R., et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 379, 895, 2012.
76. Bolli, R., et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 378, 1847, 2011.
77. Rama, P., et al. Limbal stem-cell therapy and long-term corneal regeneration. N Engl J Med 363, 147, 2010.
78. Peerbooms, J.C., et al. Positive effect of an autologous platelet concentrate in lateral epicondylitis in a double-blind randomized controlled trial: platelet-rich plasma versus corticosteroid injection with a 1-year follow-up. Am J Sports Med 38, 255, 2010.
79. Gosens, T., et al. Ongoing positive effect of platelet-rich plasma versus corticosteroid injection in lateral epicondy-litis: a double-blind randomized controlled trial with 2-year follow-up. Am J Sports Med 39, 1200, 2011.
80. Castricini, R., et al. Platelet-rich plasma augmentation for arthroscopic rotator cuff repair: a randomized controlled trial. Am J Sports Med 39, 258, 2011
81. Rodeo, S.A., et al. The effect of platelet-rich fibrin matrix on rotator cuff tendon healing: a prospective, randomized clinical study. Am J Sports Med 40, 1234, 2012.
82. de Vos, R.J., et al. Platelet-rich plasma injection for chronic Achilles tendinopathy: a randomized controlled trial. JAMA 303, 144, 2010.
83. Boilard, E., et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 327, 580, 2010.
84. Marolt, D., et al. Engineering bone tissue from human embryonic stem cells. Proc Natl Acad Sci USA 109, 8705, 2012.
85. Takahashi, K., and Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663, 2006.
86. Yamanaka, S., and Blau, H.M. Nuclear reprogramming to a pluripotent state by three approaches. Nature 465, 704, 2010.
87. Stadtfeld, M., and Hochedlinger, K. Induced pluripotency: history, mechanisms, and applications. Genes Dev 24, 2239, 2010.
88. Amabile, G., and Meissner, A. Induced pluripotent stem cells: current progress and potential for regenerative medicine. Trends Mol Med 15, 59, 2009.
89. Sommer, C.A., and Mostoslavsky, G. The evolving field of induced pluripotency: Recent progress and future challenges. J Cell Physiol 228, 267, 2013.
90. Anokye-Danso, F., et al. Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell 8, 376, 2011.
91. Warren, L., et al. Highly efficient reprogramming to pluri-potency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7, 618, 2010.
92. Miyoshi, N., et al. Reprogramming of mouse and human cells to pluripotency using mature microRNAs. Cell Stem Cell 8, 633, 2011.
93. Bhutani, N., et al. Reprogramming towards pluripotency requires AID-dependent DNA demethylation. Nature 463, 1042, 2010.
94. Qian, L., et al. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature 485, 593, 2012.
95. Song, K., et al. Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature 485, 599, 2012.
96. Jayawardena, T.M., et al. MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to car-diomyocytes. Circ Res 110, 1465, 2012.
97. Huang, P., et al. Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. Nature 475, 386, 2011.
98. Vierbuchen, T., et al. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 463, 1035, 2010.
99. Zhao, T., et al. Immunogenicity of induced pluripotent stem cells. Nature 474, 212, 2011.
100. Lister, R., et al. Hotspots of aberrant epigenomic repro-gramming in human induced pluripotent stem cells. Nature 471, 68, 2011.
101. Boulting, G.L., et al. A functionally characterized test set of human induced pluripotent stem cells. Nat Biotechnol 29, 279, 2011.
102. Diekman, B.O., et al. Cartilage tissue engineering using differentiated and purified induced pluripotent stem cells. Proc Natl Acad Sci USA 109, 19172, 2012.
103. Gilbert, P.M., et al. Substrate elasticity regulates skeletal muscle stem cell self-renewal in culture. Science 329, 1078, 2010.
104. Johnson, K., et al. A stem cell-based approach to cartilage repair. Science 336, 717, 2012.
105. Shimono, K., et al. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-gamma agonists. Nat Med 17, 454, 2011.
106. Fountain, H. A first: organs tailor-made with body's own cells. New York Times, September 16, 2012.